Articles related to Nephrology

Hypomagnesemia, prevalent in patients with type 2 diabetes and those in intensive care, is often underdiagnosed due to nonspecific symptoms and lack of routine serum magnesium measurements.

Semaglutide has been shown to reduce the risk of major kidney disease events and cardiovascular mortality in patients with type 2 diabetes and chronic kidney disease.

In a challenging case of polyarteritis nodosa, angiography and histopathology provided crucial diagnostic insights, leading to successful management through tailored immunosuppressive therapy.

In patients with type 2 diabetes and stage 5 chronic kidney disease, the use of SGLT2 inhibitors is associated with a lower risk of initiating dialysis and experiencing major cardiovascular events, providing a promising therapeutic avenue in a population at elevated risk.

In patients with chronic kidney disease, the elevated troponin challenge necessitates a nuanced approach, integrating serial measurements and clinical context to discern acute coronary syndrome from chronic elevations, thereby informing targeted management strategies.

SGLT-2 inhibitors have emerged as a cornerstone in managing HFrEF and CKD, demonstrating substantial reductions in cardiovascular and renal adverse outcomes. This class of medications is reshaping the therapeutic approach in patients with these comorbid conditions, providing a dual benefit that was once considered challenging to achieve.